<DOC>
	<DOCNO>NCT00185198</DOCNO>
	<brief_summary>The purpose study investigate effect testosterone replacement therapy call Testogel men PADAM . The effect body composition ( lean , fat bone ) symptoms PADAM safety study .</brief_summary>
	<brief_title>Efficacy Safety TestogelÂ® Men With Partial Androgen Deficiency Aging Males ( PADAM )</brief_title>
	<detailed_description>The study previously post Schering AG , Germany . Schering AG , Germany rename Bayer Schering Pharma AG , Germany . Bayer Schering Pharma AG , Germany sponsor trial .</detailed_description>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Symptomatic hypogonadism Willing avoid significant change pattern physical exercise lifestyle duration study Patients contraindication testosterone use</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Partial androgen deficiency age male ( PADAM )</keyword>
</DOC>